EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Celldex Therapeutics EBITDA Margin % Related Terms
Celldex Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDX vs IMNM, ELVN, VERA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Celldex Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics (CLDX) has a EBITDA Margin % of -557,206.67% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celldex Therapeutics and its competitors. According to the industry distribution chart, Celldex Therapeutics ranks #912 out of 943 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Celldex Therapeutics' EBITDA Margin % too high?
Celldex Therapeutics' current EBITDA Margin % is -557,206.67%. Based on the distribution chart, Celldex Therapeutics ranks #912 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' EBITDA Margin % compare to IMNM and ELVN?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #912 out of 943 companies for EBITDA Margin %. This places Celldex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current EBITDA Margin % is -557,206.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current EBITDA Margin % is -557,206.67%. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current EBITDA Margin % is -557,206.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
EBITDA Margin %: -557,206.67%
GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score
Get the complete analysis for CLDX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
